News
ProfoundBio to Highlight Programs and Technology at AACR 2022 Annual Meeting; Welcomes Zhu Chen, PhD, as Chief Scientific Officer
普方生物宣布将在第33届国际分子靶标与癌症治疗大会上展示其旨在扩大抗体偶联药物（ADC）治疗窗口的新型药物连接子技术
ProfoundBio Completed $55+ Million USD Series A Financing
Previous page
1
2
Next page
Contact us
Copyright © 2021 ProfoundBio (Suzhou) Co., Ltd. All rights reserved. 苏ICP备2021002620号 Powered by www.300.cn